Product References

 

for reprints please contact office@meridian.biopharm.com for reprints please contact office@meridian.biopharm.com

MB311: Humanized anti Lewis Y monoclonal antibody
Bauernhofer T, Samonigg H, Regitnik P, Weitzer W, Lileg B, Waxenecker G, Wiederkum S, Kainer M, Schuster, M Loibner, H Fido, M Kircheis R, Nechansky A. (2014) Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion. J. Cancer Therapy (5): 28-37.

Oruzio DV, Waxenecker G, Aulmann C, Märkl B, Wagner T, Mudde GC, Schuster M, Eller N, Mayer Stranner S, Himmler G, Loibner H, Schlimok G, Kircheis R, Nechansky A. (2012) Phase I dose escalation study with Le Y carbohydrate specific humanized mAb IGN311. J. Cancer Therapy (2): 760-771.

Farhan H, Schuster C, Klinger M, Weisz E, Waxenecker G, Schuster M, Sexl V, Mudde GC, Freissmuth M, Kircheis R. (2006) Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J. Pharmacol. Exp. Ther. (319): 1459-1466.
Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V. (2004) Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res., 64: 1087-1093.

MB314: De-fucosylated humanized anti Lewis Y monoclonal antibody
Kircheis R, Halanek N, Mayer M, Hajszan K, Jost W, Altmann F, Gorr G, Nechansky A. (2012). Correlation of ADCC with cytokine release induced by the stably expressed glyco-engineered humanized Lewis Y specific monoclonal antibody MB314. MAbs 4(4):532-41.
Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G, Kircheis R. (2007) Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Molecular Immunology 44:1826-1828.
Schuster M, Jost W, Mudde GC, Wiederkum S, Schwager C, Janzek E, Altmann F, Stadlmann J, Stemmer C, Gorr G. (2006) In vivo glyco-engineered antibody with improved lytic potential produced by a non-mammalian expression system. Biotechnol J. 2(6):700-8.